Sou Hu Cai Jing·2025-06-24 13:51Core Viewpoint - The article discusses the emergence of 18 "cold potential stocks" in the A-share market that have experienced three consecutive years of decline, attracting institutional investors who see potential for recovery and growth [1][4]. Group 1: Selection Criteria for "Cold Potential Stocks" - The stocks selected have shown a consistent decline over three years, indicating a lack of market interest, possibly due to industry cycles or company-specific issues [3]. - Three hard indicators were used for selection: - Performance must be solid, with a projected net profit exceeding 300 million in 2024 and maintaining over 30 million in Q1 2025 [3]. - At least five institutions must give a "buy/increase" rating, with a consensus forecast of over 30% net profit growth for the year [3]. - The time dimension is crucial, as three years of decline have eliminated short-term speculative investors, leaving only fundamental value players [3]. Group 2: Industry Insights - The power equipment industry has the highest representation among the selected stocks, attributed to: - A reversal in industry cycles, where previous expansions in renewable energy (solar, storage, wind) have led to a more optimized competitive landscape and genuine profit realization [5]. - A surge in demand driven by AI computing needs and renewable energy, with overseas orders for wind and solar energy showing signs of recovery [5]. - Institutions view the prolonged decline in stock prices as an opportunity for medium to long-term investments, as improved performance and growth rates present a favorable risk-reward scenario [6]. Group 3: Notable Stocks and Their Potential - Three standout stocks were highlighted: - Rongsheng Petrochemical, with 15 institutions recommending a buy and a projected net profit growth of nearly 300%, benefiting from a recovering refining industry [7]. - Gujia Home Furnishing, characterized by a low price-to-earnings ratio and strong institutional backing, with growth projections considered conservative [7]. - Jianyou Co., a pharmaceutical company with significant growth potential driven by its dual focus on heparin raw materials and biopharmaceuticals [7]. - Common traits among these stocks include solid performance, significant institutional interest, and strong industry fundamentals [8].